4//SEC Filing
HAMED KAMAL 4
Accession 0000950170-24-011491
CIK 0001701108other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 8:45 PM ET
Size
7.1 KB
Accession
0000950170-24-011491
Insider Transaction Report
Form 4
HAMED KAMAL
Chief Medical Officer
Transactions
- Award
Common Stock
2024-02-01+239,731→ 816,192 total - Sale
Common Stock
2024-02-02$1.37/sh−28,075$38,463→ 788,117 total
Footnotes (3)
- [F1]Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
- [F2]The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023 pursuant to a "sell to cover" provision included in the RSU Agreement.
- [F3]Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Documents
Issuer
Spero Therapeutics, Inc.
CIK 0001701108
Entity typeother
Related Parties
1- filerCIK 0001946366
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 8:45 PM ET
- Size
- 7.1 KB